Fayez Alghofaili

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Peritoneal Dialysis

Systematic Review

Coronavirus Disease

Newly Diagnosed

Top Venues

Pharmaceuticals (Basel, Switzerland)

Diseases (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Abdulaziz Yahya Sharahili, Shabir Ahmad Mir, Sahar ALDosari, Md Dilshad Manzar, Bader Mohammed Alshehri, Ayoub Al Othaim, Fayez Alghofaili, Yahya Madkhali, Kamal Shaker Albenasy, Jazi Shaydied Alotaibi
Correlation of HbA1c Level with Lipid Profile in Type 2 Diabetes Mellitus Patients Visiting a Primary Healthcare Center in Jeddah City, Saudi Arabia: A Retrospective Cross-Sectional Study. Diseases (Basel, Switzerland) 11 (4) (2023)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)